About | Hematology | Webinar

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

2025-04-28 - 2025-04

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) through continued clinical success with BRUKINSA® (zanubrutinib) and promising advancements in its pipeline assets.

Veterinary Hematology Analyzers Market is Poised to Grow at a CAGR of 5.4% to Reach US$ 1.86 Billion by 2035

2025-04-25 - 2025-04

The global veterinary hematology analyzers market is USD 1.1 billion in value in 2025. According to Fact. MR's study, the veterinary hematology analyzers market will expand at a CAGR of 5.4% and will reach USD 1.86 billion by 2035. The primary driver for this growth is increasing demand for speedy and accurate diagnostic testing among veterinary clinics due to increased pet ownership, booming livestock, and growing preventive animal care worth.

Hydroxyurea's Long-Term Efficacy in Pediatric Sickle Cell Disease (SCD):

2025-04-23 - 2025-04

Recent advances in hematology have highlighted significant progress in both clinical treatment and technological innovation. A major study has confirmed the long-term efficacy of hydroxyurea in children with sickle cell disease (SCD), showing it substantially reduces hospital visits and improves quality of life. Additionally, new research has found that inflammatory markers like C-reactive protein rise during certain phases of the menstrual cycle, potentially triggering pain crises in women with SCD. In drug development, the European Union has approved the combination of Columvi and GemOx for treating diffuse large B-cell lymphoma, while the FDA granted Fast Track status to PTX-100 for skin lymphoma. Meanwhile, combining daratumumab with lenalidomide has been shown to significantly improve minimal residual disease (MRD) negativity rates in multiple myeloma patients, marking a deeper therapeutic response. On the technological front, a machine learning model now predicts transplant risks in myelofibrosis patients with greater precision, and a novel AI-based approach is enhancing the classification of white blood cells while preserving data privacy. These advancements collectively signal a promising future for personalized and effective hematologic care.

Study: Differences in Malignant Hematologic Neoplasm Cytokine Storm Etiology Have Clinically Meaningful Effects

2025-04-22 - 2025-04

In patients with malignant hematologic neoplasms, cytokine storm (CS) can be initiated by many different causes. Among these are malignant neoplasm–associated hemophagocytic lymphohistiocytosis (MN-HLH), COVID-19 infection, and chimeric antigen receptor (CAR) T-cell therapy. A multidepartmental team of investigators from the University of Texas MD Anderson Cancer Center, Houston, conducted a study to see whether cases of CS outcomes vary by etiology.1

Hematology Diagnostics Market By Product Type (Instrument and Consumables), By Test Type (Complete Blood Count, Hemoglobin Testing, Hematocrit Testing,

2025-04-21 - 2025-04

This growth is primarily driven by the increasing demand for accurate and comprehensive diagnostic solutions, as well as the rising prevalence of chronic diseases, blood disorders, and lifestyle-induced health conditions. Blood tests, such as the complete blood count (CBC), play a critical role in diagnosing both hematological and non-hematological conditions.

Faster, cheaper, better: the rise of blood tests for Alzheimer’s

2025-04-19 - 2025-04

Ellen was on a cycling holiday in September 2023 when her memory and thinking skills began to falter. Riding behind her husband on their bright green tandem bike through the rolling hills of Europe’s Iberian Peninsula, Ellen found herself struggling to follow simple navigation cues.

When she returned home to Missouri, Ellen (who asked that only her middle name be used) underwent a comprehensive evaluation, including a new blood test designed to detect proteins linked to the plaques and tangles in the brain that characterize Alzheimer’s disease. The results confirmed what her friends and family had quietly feared: Ellen was in the early stages of Alzheimer’s, a devastating form of dementia that erodes memory and affects millions of people worldwide.

13th Emirates Hematology Conference explores latest innovations in diagnosis, tr .. Read more at: https://health.economictimes.indiatimes.com/news/industry/13th-emirates-hematology-conference-explores-latest-innovations-in-diagnosis-treatment-of-blood-di

2025-04-17 - 2025-04

The breadth of data we’re presenting at ASH underscores BRUKINSA’s role as a best-in-class treatment for CLL and highlights BeiGene’s leadership in advancing the treatment landscape for B-cell malignancies,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “BRUKINSA shows tremendous promise for patients as a monotherapy and as a backbone for best-in-class combinations. The combination of BRUKINSA and our investigational BCL2 inhibitor, sonrotoclax, demonstrated significant potential as a first-line therapy in CLL, with a 99% overall response rate, best uMRD rate of 92%, and was generally well-tolerated at a median follow-up of 19.4 months; this combination is expected to offer better efficacy than a fixed-dose V-O regimen. Additionally, our investigational BTK degrader could become a first-in-class treatment option for patients with CLL and other BTK-driven B-cell malignancies based on the results of data presented at ASH. BeiGene is primed to shape the future of CLL treatment and aims to meet the needs of CLL patients globally.”

Webinar on Hematology

useful links

Latest News